Search

for
Search:

Sort by

Research

870-900 / 1000+ results

research 532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

2 citations , September 2022 in “Annals of Oncology”

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis

research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis

1 citations , April 2016 in “Journal of The American Academy of Dermatology”

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

research Th1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata

May 2025

CD4 T cells need IFN-γ to cause hair loss in alopecia areata.

research A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

September 2025 in “Value in Health”

research Hair Growth in a Patient with Alopecia Areata on Tocilizumab

1 citations , January 2021 in “Skin appendage disorders”

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

research Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise

August 2025 in “Australasian Journal of Dermatology”

Experts created guidelines for who in Australia can get subsidized JAK inhibitor therapy for alopecia areata.

research Janus kinase inhibitors for alopecia areata: a review of clinical data

4 citations , May 2025 in “Frontiers in Immunology”

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

research ISID1343 - Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia

May 2023

The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.

research EFFECTS OF LIRAGLUTIDE ON VISCERAL ADIPOSITY INDEX IN WOMAN OF REPRODUCTIVE AGE WITH PREDIABETES

January 2024 in “Wiadomości Lekarskie”

Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.

research Lentiviral Vector-Mediated Gene Transfer to Human Hair Follicles

6 citations , February 2009 in “Journal of Investigative Dermatology”

Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

research Experience with oral tofacitinib in severe alopecia areata with different clinical responses

11 citations , February 2021 in “Journal of Cosmetic Dermatology”

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

research LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties

July 2024 in “Journal of Investigative Dermatology”

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Pityriasis Amiantacea: A Unique Presentation of Psoriasis Associated With Tumour Necrosis Factor-Alpha Inhibitor Therapy

research P07 Pityriasis amiantacea: a unique presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy

1 citations , September 2023 in “Rheumatology advances in practice”

A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.

Cyproterone and Finasteride Treatment in a 74-Year-Old Man with Hypersexuality

research Cyproterone/finasteride

July 2016 in “Reactions Weekly”

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials

November 2025 in “SKIN The Journal of Cutaneous Medicine”

The study found that Baricitinib (Bari), a Janus kinase inhibitor, is effective and safe for treating severe alopecia areata (AA) in both adolescents and adults. In the BRAVE-AA trials, 257 adolescents and 1,200 adults were treated with either Bari 4mg, Bari 2mg, or a placebo. At 36 weeks, 42.4% of adolescents on Bari 4mg achieved a SALT score of less than 20, compared to 34% of adults. Adolescents showed higher response rates despite having more severe disease at baseline, indicating the potential benefits of early intervention. Common side effects included headache, acne, and upper respiratory tract infections.

research The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection

8 citations , December 2023 in “International Journal of Molecular Sciences”

Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.

Repurposing FDA Approved Drugs for Psoriasis Indications Through Integrated Molecular Docking, One-SVM Algorithm, and Molecular Dynamics Simulation Approaches

research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches

July 2025 in “Scientific Reports”

Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

research Hair-cycle changes in two patients taking tocilizumab

6 citations , August 2013 in “Joint Bone Spine”

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

research [Successful treatment of "steroid-immunosuppressant resistant" polymyositis with immunoadsorption].

1 citations , November 1991 in “PubMed”

Immunoadsorption successfully treated a man's resistant polymyositis.

research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

1 citations , September 2023 in “Dermatology and Therapy”

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

research Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study

14 citations , January 2025 in “Journal of Dermatological Treatment”

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy

September 2023 in “JAAD case reports”

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Alopecia After Switch to Tenofovir Alafenamide in Six African American Women

research Alopecia After Switch to Tenofovir Alafenamide in 6 African American Women

5 citations , June 2019 in “Open Forum Infectious Diseases”

Six African American women experienced hair loss after switching to a new HIV medication.

research MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?

April 2024 in “The Journal of urology/The journal of urology”

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

research Correspondence

November 1998 in “Journal of The European Academy of Dermatology and Venereology”

A man's skin cancer improved and some of his hair grew back after treatment with a special light therapy and a medication.

research Polynucleotides as a novel therapeutic approach in androgenetic alopecia: an analysis of effectiveness and safety

February 2025 in “Archives of Dermatological Research”

Polynucleotides effectively promote hair regrowth in androgenetic alopecia without serious side effects.

research Injectable-platelet-rich fibrin-smart blood with stem cells for the treatment of alopecia: A report of three patients

18 citations , January 2019 in “International journal of trichology”

The treatment improved hair growth in three patients with alopecia.

research Enzalutamide/finasteride/goserelin/zoledronic-acid

July 2024 in “Reactions Weekly”

← Previous page Next page →